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GADD45A and CDKN1A are 
involved in apoptosis and cell cycle 
modulatory effects of viscumTT 
with further inactivation of the 
STAT3 pathway
Susann Kleinsimon1,2, Enya Longmuss3, Jana Rolff4, Sebastian Jäger5, Angelika Eggert1, 
Catharina Delebinski1 & Georg Seifert1
ViscumTT, a whole mistletoe preparation, has shown synergistic induction of apoptosis in several 
pediatric tumor entities. High therapeutic potential has previously been observed in Ewing’s sarcoma, 
rhabdomyosarcoma, ALL and AML. In this study, we analyzed modulatory effects on the cell cycle by 
viscumTT in three osteosarcoma cell lines with various TP53 statuses. ViscumTT treatment induced 
G1 arrest in TP53 wild-type and null-mutant cells, but S arrest in TP53 mutant cells. Blockage of G1/S 
transition was accompanied by down-regulation of the key regulators CDK4, CCND1, CDK2, CCNE, 
CCNA. However, investigations on the transcriptional level revealed secondary TP53 participation. 
Cell cycle arrest was predominantly mediated by transcriptionally increased expression of GADD45A 
and CDKN1A and decreased SKP2 levels. Enhanced CDKN1A and GADD45A expression further played 
a role in viscumTT-induced apoptosis with involvement of stress-induced MAPK8 and inactivation of 
MAPK1/3. Furthermore, viscumTT inhibited the pro-survival pathway STAT3 by dephosphorylation of 
the two sites, Tyr705 and Ser727, by down-regulation of total STAT3 and its direct downstream targets 
BIRC5 and C-MYC. Moreover, tests of the efficacy of viscumTT in vivo showing reduction of tumor 
volume confirmed the high therapeutic potential as an anti-tumoral agent for osteosarcoma.
ViscumTT is a whole mistletoe extract resulted from combination of two single extracts (viscum and TT). Viscum 
represents the aqueous part and is similar to conventional mistletoe preparations. It contains mainly hydrophilic 
mistletoe lectin I (ML I) as well as viscotoxins, whereby ML I is the main active constitutes and functioned as 
marker substance1,2. ML I is a glycoprotein belonging to the ribosome-inactivating proteins (RIP) type II and 
consists of a binding (B) and an activity (A) chain. The B chain binds to D-galactose at the cell surface and the 
A chain mediates its enzymatic activity in the cell3,4. TT represents the lipophilic part of viscumTT and con-
tains mainly oleanolic- (OA) and betulinic acid (BA). Both are nearly water-insoluble and were solubilized with 
2-hydroxypropyl-ß-cyclodextrin for application in watery environment5. OA is distinctly higher concentrated in 
the TT extract and is used as marker substance. For both main active constituents of viscumTT, ML I and OA, 
various anti-tumoral properties such as induction of apoptosis, cell cycle arrest and immunomodulatory func-
tions have been described6–11. In previous studies, we have shown synergistic effects in vitro as well as high thera-
peutic effectiveness in vivo in a panel of tumor entities when both single extracts were combined (viscumTT)12–18.
The basic mechanism of action of viscumTT is not fully understood. Sequence analysis and proteomic profiling 
of viscumTT-treated Ewing’s sarcoma cells have provided information about the activated pathways19. ViscumTT 
and its single extracts viscum and TT are involved in activation of the stress-mediated mitogen-activated kinase 
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(MAPK8) pathway, oxidative stress and Toll like receptor signaling19. European and Korean mistletoe mediated 
induction of apoptosis via activation of the phosphatidylinositol 3/protein kinase B (PI3K/AKT) pathway20 and 
mitogen-activated protein kinase 8/14 (MAPK8/MAPK14)21 signaling. Down-regulation of inhibitor of apoptosis 
proteins (IAPs) such as baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, survivin) and X-linked 
inhibitor of apoptosis protein (XIAP) was observed in Ewing’s sarcoma, osteosarcoma and rhabdomyosarcoma 
cell lines12–14. Signal transducer and activator of transcription 3 (STAT3) which is often constitutively activated in 
diverse tumors22 was inhibited by a synthetic oleanolic derivative in multi-drug resistant osteosarcoma cells23 as 
well as by a fermented mistletoe preparation in gliomas24.
Tumor protein 53 (TP53) is one of the most mutated genes in human cancers25. Encoded tumor suppressor 
protein functions as key regulator of many cell processes including cell cycle regulation, senescence, survival, 
proliferation and apoptosis26. Around 10-20% of osteosarcomas have rearranged TP53 and dysregulated cell 
cycles27. In healthy cells, TP53 is immediately induced and contributes to transcriptional activation of a range 
of target genes, e.g. BCL2-associated X (BAX)28, growth arrest and DNA damage inducible alpha (GADD45A)29, 
cyclin-dependent kinase inhibitor 1 A (CDKN1A)30 and FAS31, after cellular stress and DNA damage. In many 
cases, TP53 is not strictly required for drug-induced cell death and its contribution depends on dose, tissue and 
mutational background of the tumor32. Today, influencing cell cycle regulatory proteins may offer a promising 
approach in cancer therapy. Therefore, positive (cyclins, CCNs) and negative (cyclin-dependent kinase inhibitors, 
CDKNs) regulators of cyclin-dependent kinases (CDKs) are also of interest33.
Our present study reveals new insights into the mechanism of action of viscumTT regarding alteration of cell 
cycle progression and induction of apoptosis in osteosarcoma in vitro. We report the involvement of GADD45A 
and CDKN1A and show that STAT3 plays a role in molecular events. We also demonstrate high therapeutic effi-
cacy of viscumTT in an osteosarcoma xenograft model.
Results
Viscum, TT and viscumTT inhibit cell cycle progression. Synchronized osteosarcoma cell lines were 
treated with viscum, TT and viscumTT, and cell cycle distribution was analyzed at different time points. Viscum 
significantly arrested TP53 wild-type (U2OS, Fig. 1A) and null-mutant (Saos-2) cells in G1 phase, whereas 
TP53 mutant cells (143B) remained in S phase (Fig. 1B). On the other hand, TT led to G1 arrest in all cell lines. 
Likewise, viscumTT affected the cell cycle in TP53 wild-type and null-mutant cells in G1 phase, whereas TP53 
mutant cells showed higher cell counts in S phase. In U2OS cells after TT and in Saos-2 cells after all treatments 
Figure 1. Viscum, TT and viscumTT have cell cycle modulatory effects. U2OS (A), 143B (B) and Saos-2 cells 
(C) were analyzed regarding to cell cycle distribution after viscum, TT and viscumTT treatment at different time 
points. Ethanol-fixed cells were stained by propidium iodide and analyzed by FACS. For viscum, mistletoe lectin 
(ML) 10 ng/mL, for TT, oleanolic acid (OA) 60 µg/mL and for viscumTT, ML+OA 5 ng/mL + 50 µg/mL were 
used. The means ± SD of cells in % in cell cycle phase were displayed in comparison to ctrl (n ≥ 3). Significant 
results are indicated as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 related to untreated control (ctrl). 
Each experiment was independently performed thrice (n ≥ 3).
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an increase in the number of cells in G2/M phase after 48 h was observed, indicating that complete stagnation 
had not occurred. The results of all treatments point to a cell cycle inhibitory effect by viscumTT in each cell line.
Viscum, TT and viscumTT down-regulate CDKs and CCNs. To investigate the observed cell cycle 
arrests, the key regulators of G1/S transition, CDK4 and cyclin D1 (CCND1), as well as CDK2 and CCNE/A 
protein levels were analyzed by western blotting after 24 h. CDK4 and CCND1 were strongly down-regulated after 
viscum, TT and viscumTT treatment in all three cell lines (Fig. 2A–C). CDK2, CCNE and CCNA were similar 
down-regulated in U2OS cells, but lower in 143B cells. CCNE expression was not affected in Saos-2 cells after vis-
cum and TT treatment. The observed results suggest a direct effect on cell cycle regulatory proteins and confirm 
prevention of G1/S phase progression.
Viscum, TT and viscumTT alter expression pattern of cell cycle-related genes. For a first over-
view, direct effects on cell cycle regulatory target genes were analyzed using RT² Profiler™ PCR Array Human Cell 
Cycle after 24 h of treatment. The gene expression patterns of all cell lines showed alterations. Figure 3A–C show 
up- and down-regulated genes starting from 2-fold regulation to control as cut-off for significant change. After 
matching the results, five genes were found that were up-regulated and one gene which were down-regulated in 
each cell line after viscumTT treatment. One of these five up-regulated genes was GADD45A which showed a 
30-fold increase in TP53 wild-type and mutant cells after viscum and viscumTT treatment, but less in null mutant 
cells. CDKN1A a second up-regulated gene was triggered predominantly by TT and viscumTT treatment and to a 
distinctly greater extent in TP53 mutant and null-mutant cells. SKP2 as only down-regulated gene in all three cell 
lines showed approximately 70-fold decrease in TP53 wild-type (U2OS) and around 20-fold decrease in mutant 
cells (143B) after viscum and viscumTT incubation. Null-mutant cells (Saos-2) showed only a weak change. 
Viscum, TT and viscumTT altered the transcriptional level of several cell cycle genes. Two of five up-regulated 
genes (GADD45A, CDKN1A) and SKP2 as only down-regulated gene with the highest fold change were analyzed 
further. All fold changes of altered cell cycle genes are listed in supplementary information including clustergram 
to each cell line (Table S1A-S1C, Figure S1A–S1C).
CDKN1A, GADD45A and SKP2 are transcriptionally affected by viscum, TT and viscumTT. In 
order to validate the RT² Profiler™ PCR Array results, CDKN1A, GADD45A and SKP2 expression was exam-
ined over the course of time using RT-qPCR. Viscum and viscumTT increased CDKN1A to a greater extent 
in TP53 wild-type (up to 8-fold and 13-fold increase, respectively) and mutant cells (up to 7-fold and 15-fold 
increase, respectively), whereas TT (up to 8-fold increase) had the same effect in both cell lines. (Fig. 4A–C). 
Significant up-regulation started 6 h after treatment, peaked at 14 h for viscum/viscumTT in all cell lines and at 
24 h for TT in Saos-2 cells. Likewise, GADD45A was periodically induced in each cell line but predominantly 
expressed by viscum and viscumTT, although the level was lower after viscumTT treatment. However, GADD45A 
was more strongly up-regulated in TP53 wild-type (up to 56-fold after viscum and 44-fold after viscumTT) and 
mutant cells (up to 36-fold after viscum and 24-fold after viscumTT) than in null-mutant cells (Fig. 4A–C). TT 
did not influence the GADD45A level in any of the three cell lines. On the other hand, SKP2 was drastically 
down-regulated (up to 140-fold decrease) in TP53 wild type (U2OS) and mutant (143B) cells after viscum and 
viscumTT treatment (Fig. 4A,B), whereas TT led to an 8-fold decrease (Fig. 4A,B). In TP53 null-mutant (Saos-
2) cells, the effect was weaker (approximately 3-fold decrease, Fig. 4C) after all treatments. The results confirm 
CDKN1A, GADD45A and SKP2 as transcriptional targets for viscum and viscumTT, while TT mainly influenced 
the expression of CDKN1A but not of GADD45A.
Figure 2. Key regulators of G1/S transition are down-regulated by each treatment. Whole cell lysates were 
analyzed by western blotting after 24 h of treatment and protein expression of cyclin A (CCNA), cyclin E 
(CCNE), cyclin-dependent kinase 2 (CDK2), cyclin D1 CCND1) and cyclin-dependent kinase 4 (CDK4) was 
detected. Cropped blots display representative images from three independent experiments of U2OS (A), 
143B (B) and Saos-2 (C) cells after viscum (ML) 10 ng/mL, TT, oleanolic acid (OA) 60 µg/mL and viscumTT, 
ML+OA 5 ng/mL + 50 µg/mL treatment. ML was used as marker substance for viscum and OA for TT. 
GAPDH was used as loading control.
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Viscum, TT and viscumTT influence CDKN1A, GADD45A and SKP2 protein expression. After 
investigation of gene expression, CDKN1A, GADD45A and SKP2 protein levels were analyzed by western blot-
ting over the course of time. Viscum and viscumTT led to down-regulation of CDKN1A in TP53 wild-type 
(U2OS) and mutant (143B) cells after 6/9 h of incubation, whereas null-mutant cells showed similar protein 
expression to control cells (Fig. 5A–C). TT initiated down-regulation of CDKN1A after 14 (U2OS) or 18 h 
Figure 3.  Viscum, TT and viscumTT alter cell cycle-related genes. Expression of cell cycle-related genes of 
U2OS (A), 143B (B), Saos-2 (C) cells were analyzed by RT² Profiler™ PCR Array after 24 h of viscum, TT and 
viscumTT treatment. For viscum, mistletoe lectin I (ML) 10 ng/mL, for TT, oleanolic acid (OA) 60 µg/mL and 
for viscumTT, ML+OA 5 ng/mL + 50 µg/mL were used. Array was performed once for each cell line and the 
fold-regulation cut-off was set to 2 and the p-value cut off was set to p ≤ 0.05 by the software.
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(143B). In Saos-2 cells CDKN1A was higher in comparison to control after 9 h. GADD45A was distinctly higher 
expressed in U2OS cells after 6-14 h of viscum and viscumTT incubation. 143B cells showed stronger induction 
at 24 h in comparison to control after both treatments, whereas in Saos-2 cells a prolonged increase after start-
ing at 14/18 h was seen. TT did not affect GADD45A in any cell line. SKP2 was distinctly down-regulated after 
viscum and viscumTT in U2OS, after viscum, TT and viscumTT in 143B and after TT and viscumTT in Saos-2 
cells (Fig. 5A–C). Taken together, a divergence between gene and protein expression was observed in the case of 
CDKN1A whereas GADD45A and SKP2 protein correlated with the transcriptional level.
Knock down of CDKN1A and GADD45A attenuates viscum, TT and viscumTT effect. To further 
examine the role of CDKN1A and GADD45A in inhibition of cell cycle progression and induction of apoptosis, 
siRNA knock down experiments were performed. The viscum-induced G1 arrest (55.2%) was equally abolished 
when TP53 wild type (U2OS) cells were transfected with either siGADD45A or siCDKN1A (Fig. 6A). The com-
bination of both siRNAs reduced the number of cells in G1 phase (41.4%) but was also associated with a slight 
increase of cells in G2/M phase compared to single siRNAs in U2OS cells. Neither variant of siRNA had any 
influence on untreated U2OS cells (Figure S2). The TT-mediated G1 arrest was not prevented by knock down 
of GADD45A but attenuated by siCDKN1A and combined siRNAs (Fig. 6A). G1 arrest after viscumTT treat-
ment was equally inhibited by all three knock down variants in these cells (Fig. 6A). In TP53 mutant (143B) 
cells viscum led to a non-significant increase of cells in S phase but this effect was reduced by siGADD45A, 
left unchanged by siCDKN1A and enhanced by combined siRNAs. Furthermore, the TT-mediated G1 arrest 
increased after GADD45A knock down and decreased after siCDKN1A and the combination. No induction of 
cell cycle arrest was seen after viscumTT treatment after 24 h, whereas G1 arrest was initiated after siGADD45A 
(Fig. 6B). In contrast, in apoptosis experiments, siGADD45A prevented a viscum-induced effect in U2OS cells, 
and both other siRNA variants showed a similar inhibition in U2OS cells. Weak apoptosis was rescued by siCD-
KN1A and almost completely by siRNA combination in 143B cells, but not by siGADD45A. Furthermore, in 
TP53 wild-type cells knock down of CDKN1A and both genes led to stronger induction of apoptosis after TT 
and viscumTT treatment. In 143B cells each siRNA variant was effective in viscum, TT and viscumTT treat-
ment, but CDKN1A knock down led to the greatest inhibition of apoptosis by viscumTT. Taken together, these 
Figure 4. Cell cycle alterations based on up-regulation of CDKN1A and GADD45A and down-regulation of 
SKP2. Gene expression of CDKN1A, GADD45A and SKP2 was detected between 3 and 24 h. U2OS (A), 143B 
(B) and Saos-2 (C) cells were treated either with viscum, TT or viscumTT. The means of n-fold regulation ± SD 
related to untreated control (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001) are shown. Each experiment 
was independently performed thrice (n ≥ 3).
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results illustrate differences between viscum, TT and viscumTT treatment regarding the role of GADD45A and 
CDKN1A in cell cycle arrest and apoptosis. Furthermore, involvement of either GADD45A or CDKN1A may be 
influenced by the TP53 status of the cells.
ViscumTT inactivates MAPK1/3 and activates MAPK8 pathway. In view of the direct interac-
tion of GADD45A and MAPK pathways, MAPK8 and MAPK1/3 activation was analyzed after viscum, TT 
and viscumTT treatment by western blotting. In both cell lines MAPK8 was weakly and MAPK1/3 strongly 
activated in control cells. After treatment with viscum and viscumTT a distinct increase in phosphorylated 
MAPK8 as well as a decrease in activated MAPK1/3 was seen in both cell lines (Fig. 7A,B). Additionally, after 
TT-treatment MAPK8 was slightly phosphorylated in both cell lines. MAPK1/3 was faintly enhanced in 143B 
cells. Both cell lines were further incubated with MAPK8 inhibitor SP600125. U2OS cells were sensitive to viscum 
(Figure S3A,B) and apoptosis was prevented up to 35% by SP600125 (Fig. 7C). As seen in an earlier study, 143B 
cells were nearly resistant to viscum14 but induction of apoptosis was reduced up to 50% (Fig. 7D). Interestingly, 
viscumTT-induced apoptosis in both cell lines and the TT-effect in 143B cells was significantly enhanced when 
preincubated with SP600125. These results show that activation of MAPK8 with simultaneous inactivation of 
MAPK1/3 is a molecular event in viscumTT-mediated effects.
ViscumTT inhibits STAT3 pathway and its anti-apoptotic downstream targets. Phosphorylation 
of transcription factor STAT3 at Ser727 is associated with MAPK8 and MAPK1/3, whereas STAT3 phosphoryl-
ation at Tyr705 is mainly mediated by IL-6 and Janus kinases (JAK). In order to determine whether viscum, TT 
and viscumTT influence STAT3 protein levels and phosphorylation sites, cells were treated as described above 
and further analyzed by western blotting. Cells in both untreated controls were phosphorylated at Tyr705 and 
Ser727 (Fig. 8A,B). Viscum, TT and viscumTT led to dephosphorylation of Tyr705 and Ser727 with further total 
STAT3 degradation (Fig. 8A,B). Additionally, direct downstream targets of Tyr705 phosphorylated STAT3, such 
as BIRC5 and MYC-proto-oncogene (MYC) were effected. Therefore, BIRC5 was strongly down-regulated in 
both cell lines and MYC only in U2OS cells.
Viscum, TT and viscumTT significantly reduce tumor volume in mice xenografts. To investigate 
the further therapeutic potential of viscum, TT and visumTT, their efficacy was tested in vivo. For this purpose, 
Saos-2 xenografts were treated intratumorally six times for approximately three weeks. Viscum and TT led to a 
significant reduction of tumor volume in comparison to control group but viscumTT was more effective than 
the single extracts. In the viscumTT group the tumor volume was significantly reduced by approximately 50% 
versus the control group and a significant group effect was also revealed compared to viscum group (Fig. 9). The 
Figure 5. Viscum, TT and viscumTT affect GADD45A, CDKN1A and SKP2 on protein level. Blots 
demonstrate CDKN1A, GADD45A and SKP2 expression of whole cell lysates from U2OS (A), 143B (B) and 
Saos-2 (C) after different time points after viscum, TT and viscumTT treatment. GAPDH was used as loading 
control. Cropped blots display representative images from three independent experiments.
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mice did not show any significant changes in body weight or signs of toxicity during the study which means that 
viscum, TT and viscumTT treatment was well tolerated.
Discussion
The molecular mechanism of the synergistic anti-tumoral properties of viscumTT in diverse pediatric tumor 
entities is not fully understood12–16,19. The present study focused on a better understanding of the molecular func-
tion of viscumTT and its single extracts regarding cell cycle alterations and induction of apoptosis. We observed 
a cell cycle arrest in different phases after viscum and in G1 phase after TT treatment. Arrest in various phases 
of the cell cycle has also been described for commercial Viscum album preparations in several tumor entities34,35. 
OA-induced G1 arrest was observed in hepatocellular carcinoma cells36 and gallbladder cancer cells37 but G2/M 
arrest in pancreatic cancer cells8. Generally, cells with dysfunctional TP53 or CDKN1A lose their G1/S check-
point and are not able to arrest in G138. However, G1 arrest can be induced by various anti-cancer agents in a 
TP53-independent manner and is associated with induction of CDKN1A39,40, which was also observed in our 
study. Cell cycle arrest initiated by viscum either in G1 or S phase was also accompanied by up-regulation of 
GADD45A. In the case of DNA damage, wild-type TP53 initiates GADD45A and CDKN1A expression resulting 
in G2/M or G1/S arrest, respectively41,42. Contrary to this, TP53 wild-type cells (U2OS) arrested in G1 phase after 
viscum and viscumTT treatment through induction of GADD45A as has previously been described for another 
natural compound in cells carrying functional TP5343. Both GADD45A and CDKN1A are able to mediate their 
function in a TP53-dependent and -independent manner44–47, directly interact with41,48, and arrest cells either 
in G1/S or G2/M phase49. Our siRNA knockdown experiments showed joint upregulation of GADD45A and 
CDKN1A resulted in G1 or in S arrest (viscum, viscumTT, TP53 mutant 143B cells) as well as in induction of 
apoptosis in the present study. Curcumin, another natural compound, triggered G1 arrest and apoptosis in a 
Figure 6. GADD45A and CDKN1A are involved in cell cycle arrest and apoptosis by viscum, TT and 
viscumTT. After 48 h of siRNA transfection and further 24 h of treatment with viscum, TT and viscumTT, 
cells were analyzed by FACS regarding cell cycle distribution U2OS (A) and 143B (B) by propidium iodide 
and induction of apoptosis U2OS (C) and 143B (C) by Annexin V/propidium iodide staining. Represented are 
the means ± SD of cells in [%] in cell cycle phase and inhibition of apoptosis [%] of at least three independent 
experiments and significances are indicated as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 related to 
untreated control. Cropped blots evidence siRNA knock down and represent images from three independent 
experiments.
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human adenocarcinoma cell line in a TP53-independent fashion also via simultaneous induction of GADD45A 
and CDKN1A50. A TP53-independent apoptosis induction was described several times e.g. for conventional mis-
tletoe extracts, Korean mistletoe and recombinant mistletoe lectin but the mechanisms is not quite clear51–53. 
Additionally, in earlier studies by our group TP53 was distinctly down-regulated in a panel of tumor entities, 
also in osteosarcoma cells (Figure S3C)12,14,15. Down-regulation of TP53 might be explained by protein synthesis 
inhibitor function mediated by the ribosome inactivating A chain of the mistletoe lectins52,53. This study indi-
cates viscumTT-induced cell cycle alterations and induction of apoptosis occur in wild-type, mutant as well as 
null-mutant TP53 osteosarcoma cells. A participation of TP53 in the viscumTT mechanism of action in the wild 
type cells could not be excluded. TP53-independent apoptosis mechanism seems to be initiated by joint transcrip-
tional upregulation of GADD45A and CDKN1A after viscumTT treatment. For a better understanding, the role 
of TP53 in the viscumTT effect has to be further investigated in the future.
MAPK8 was described as a critical target of Viscum album extracts19,21,54. MAPK8 plays a dual role in response 
to cellular stress stimuli which is also described for OA-induced MAPK8 and controversially discussed. On the 
one hand, OA induces protective autophagy via MAPK8 and mechanistic target of rapamycin (mTOR) pathway 
activation in various cancer cells55,56. On the other hand MAPK8-mediated apoptosis is reported57. In connection 
with TP53 MAPK8 forms a positive feedback loop and induces apoptosis after genotoxic stress58. We recently 
reported autophagy induction by TT and viscumTT but not by viscum in Ewing’s sarcoma cells19. Interestingly, 
Figure 7. Viscum, TT and viscumTT activate stress-associated MAPK8 and inhibit survival-associated 
MAPK1/3. After lysis of U2OS (A) and 143B (B) cells after 24 h, phosphorylation of MAPK8 and MAPK1/3 
was analyzed by western blots. ß-actin (ACTB) or GAPDH were used as loading control. Cropped blots display 
representative images from three independent experiments. After pre-incubation with MAPK8 inhibitor 
SP600125 U2OS (C) and 143B (D) cells were stained by Annexin V/PI and analyzed by FACS. Displayed are 
mean percentages ± SD of inhibition of apoptosis of at least three independent experiments and significances 
are indicated as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 related to untreated control.
Figure 8. Inhibition of STAT3 pathway is involved in mechanism of action. Whole cell lysates of U2OS (A) 
and 143B (B) after 24 h were analyzed for total signal transducer and transcription factor 3 (STAT3) and its 
phosphorylation sites at Tyr705 and Ser727 as well as its direct down-stream targets baculoviral inhibitor of 
apoptosis repeat-containing 5 (BIRC5) and MYC-oncoprotein (MYC). ß-actin (ACTB) or GAPDH were used as 
loading control. Cropped blots display representative images from three independent experiments.
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the MAPK8 inhibitor SP600125 was not able to suppress apoptosis in TT and viscumTT-treated 143B and U2OS 
cells in this study or in Ewing’s sarcoma19. This phenomenon might be explain by inhibition of the OA-induced 
autophagy effect resulting in enhanced apoptosis55. Since synergistic effects of drug combinations are based on 
triggering different or the same targets in the same or related pathways59 the role of MAPK8 activation after vis-
cumTT becomes more relevant. This observation provides pointers to the molecular mechanism of the synergistic 
effect of viscumTT and hypothesizes viscum’s role as autophagy inhibitor, which will have to be investigated in 
the future. CDKN1A might be also involved in induction of autophagy by ursolic acid, another triterpene acid60. 
Since its inhibition leads to enhanced apoptosis61 this supports the hypothesis of synergistic action by viscumTT.
The survival and proliferation associated MAPK1/3 pathway was distinctly inactivated by each extract in TP53 
wild-type cells, while TT did not alter phosphorylation in TP53 mutant cells. However, MAPK1/3 activation may 
result in apoptosis in a TP53-independent mechanism62 and its inhibition led to a better effect of OA in cancer cells63.
In view of the combination of multiple active compounds in viscumTT, involvement of diverse pathways 
is very likely. The STAT3 pathway is mainly associated with survival and proliferation and often constitutively 
activated by phosphorylation at Tyr705 in cancer, also in osteosarcoma64,65. Meanwhile, other phosphorylation 
sites are known, Ser727 being commonly activated by MAPK1/366 but also negatively regulated by MAPK867,68. 
This was recently described for alternol, another natural compound, in osteosarcoma69 and for the triterpene acid 
ursolic acid70. In line with this, viscum, TT and viscumTT inactivated STAT3 at both phosphorylation sites with 
subsequent degradation of total STAT3 indicating involvement of that pathway in mistletoe action. Furthermore, 
down-regulation of the often overexpressed direct downstream targets, BIRC5 and MYC, was also observed in 
U2OS and 143B cells. BIRC5 down-regulation was already reported for these mistletoe extracts12,14,15. Depletion 
of STAT3 leads simultaneously to down-regulation of SKP2 and mediates cell cycle arrest71. SKP2 as F-box pro-
tein of the SKP1-cullin-F-box (SCF) complex catalyzes the ubiquitination of CDKN1A and CDKN1B for protein 
degradation in G1/S transition72 and may represent the key protein in STAT3 and cell cycle crosstalk. Inhibition 
of the STAT3/SKP2 axis by viscumTT marked a further important event in the mechanism of action.
The therapeutic effectiveness of viscum, TT and viscumTT in vivo was demonstrated in multiple earlier stud-
ies in diverse pediatric tumor entities13,15,19 and in murine melanoma18. In Ewing’s sarcoma and AML, viscumTT 
had the same effectiveness as standard chemotherapeutic drugs and showed good tolerability12,15. Often whole 
plant extracts are more effective in comparison to their single compounds73. In this present study we confirmed 
the high therapeutic potential of viscumTT, which reduced tumor volume to a greater extent than its single com-
ponents. Combination therapy approaches offer the advantage of triggering multiple signaling pathways and 
furthermore attacking various targets which are important for fighting cancer.
Conclusion
On the basis of our findings, we conclude that GADD45A and CDKN1A play an important role in 
viscumTT-mediated action in a TP53 non-essential manner. Further, we confirmed the involvement of MAPK8 
and evidenced inactivation of the survival pathways MAPK1/3 and STAT3. The mechanism of action was accom-
panied by down-regulation of BIRC5, MYC and SKP2. Widespread triggering of pro-apoptotic targets and inhi-
bition of survival promoting targets indicates a promising therapeutic approach for pediatric osteosarcoma.
Figure 9. ViscumTT reduces tumor volume more effective than its single extracts. Saos-2 xenografts 
were intratumorally treated with 50/70/90 mg oleanolic acid (OA)/kg (OA as marker substance for TT), 
0.75/1.25/1.75 µg mistletoe lectin (ML)/kg (ML as marker substance for viscum) or a combination thereof 
(viscumTT). Application was given twice or thrice per week in increasing concentrations whereby each 
concentration was administered twice. Control group received the solubilizing agent, 2-hydroxypropyl-ß-
cyclodextrin (CD). Images display tumor volume (A), and body weight (B). Two-way ANOVA and Bonferroni’s 
multiple comparison test was used and revealed a significant group effect. Significant effects were observed 
between the CD control group and viscum, TT and viscumTT group and between viscumTT and viscum group 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Indicated significances are related to CD control.
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Materials and Methods
Viscum album extracts. Viscum album extracts were prepared from apple tree (malus) mistletoe and 
lyophilized as described previously16,17 and were kindly provided by Birken AG (Niefern-Öschelbronn, Germany). 
In brief, intact ML I (A + B chain) in viscum extract was analyzed by ELISA74. Viscum was solubilized in phos-
phate buffered saline (PBS) resulting in a final concentration of 1 µg/mL intact ML I and <1 µg/mL viscotoxins. 
2-hydroxypropyl-ß-cyclodextrin-containing TT extract was prepared in PBS to 4000 µg/mL OA and 0.35 µg/mL 
BA. OA (TT) and ML I (viscum) were used as marker substances for concentrations.
Material and reagents. RPMI 1640, McCoy’s 5 A, penicillin, streptomycin, trypsin/EDTA (0.05%) and 
PBS were purchased from Gibco, Lifetechnologies (Darmstadt, Germany). Fetal Calf Serum (FCS) was obtained 
from Biochrom (Berlin, Germany). Protein inhibitors, molecular mass standards for SDS-PAGE, sodium dode-
cyl sulphate (SDS), dimethyl sulfoxide (DMSO) and propidium iodide (PI) were purchased from Sigma Aldrich 
(Munich, Germany). Beta-2 mercaptoethanol was purchased from AppliChem (Darmstadt, Germany).
Cell culture. The human osteosarcoma cell lines 143B, Saos-2 and U2OS were obtained from American Type 
Culture Collection (ATCC, Manassas, VA, USA). 143B cells were cultured in RPMI 1640, Saos-2 and U2OS in 
McCoy’s 5 A, both supplemented with 10% heat inactivated FCS 100 U/mL penicillin and 100 µg/mL streptomy-
cin. For the experiments, 143B and U2OS cells were seeded in 4*105 and Saos-2 cells in 1*106 onto 6-well plates. 
After 24 h attached cells were treated with viscum (ML 10 ng/mL), TT (OA 60 µg/mL) and viscumTT (5 ng/
mL + 50 µg/mL) at different time points.
Cell cycle analysis. For synchronization in G1 phase, cells were cultured in either RPMI 1640 or McCoy’s 5 A 
starvation medium with reduced FCS (0.04%) in 6-well microtiter plates for 24 h. Thereafter, cells were treated with 
viscum (ML 10 µg/mL), TT (OA 60 µg/mL) and viscumTT (ML 5 ng/mL + OA 50 µg/mL) for 3–24 h. After cells 
were harvested and washed with cold PBS, 1*106 cells were fixed with dribs and drabs ice cold 70% ethanol under 
gently vortexing. Then, fixed cells were stored at −20 °C until analyses. Within two weeks, DNA fragmentation was 
stained with propidiumiodide (PI). Briefly, fixed cells were centrifuged and washed with cold PBS and treated with 
100 µL RNAse (50 µg/mL) for 30 min at 37 °C. Finally, cells were stained with 200 µL of PI (50 µg/mL) for further 
30 min on ice, in the dark. DNA content was analyzed after exclusion of cell duplexes (FL2-A against FL2-W). Cell 
cycle phases were evaluated with Dean Jett Fox method75 and FlowJo® Software (FlowJo, Ashland, OR, USA).
RNA isolation. RNA was isolated by spin columns using NucleoSpin® RNA Kit (Machery&Nagel, Düren, 
Germany). Therefore, cells were incubated with viscum, TT and viscumTT in 6-well plates as described above. 
Afterwards, cells were harvested after various time points and RNA was isolated according to the manufacturer’s 
protocol. Concentration and purity was determined by OD 260/280 using NanoDrop™ 2000 spectrophotometer 
(Thermo Scientific, Dreieich, Germany). RNA integrity was checked on a denaturing agarose gel.
RNA to cDNA transcription. cDNA was synthesized using High Capacity RNA-to-cDNA™Kit (Applied 
Biosystems™, Darmstadt, Germany) and 500 ng RNA of cells were transcribed according to the manufacturer’s 
protocol.
RT² Profiler™ PCR Array of cell cycle genes. Alterations in 84 cell cycle genes were analyzed by RT² 
Profiler™ PCR Array Human Cell Cycle (Qiagen, Hilden, Germany). For this, untreated control cells and cells 
treated with viscum, TT and viscumTT for 24 h were investigated. Array analysis was performed with all three cell 
lines according to the manufacturer’s protocol. Briefly, cDNA templates were prepared in SYBR® Green master 
mix and 25 µL of each sample were added to the SYBR® Green optimized primers. Then a standard quantitative 
reverse transcription PCR (RT-qPCR) program was run (10 min, 95 °C; 15 s, 95 °C and 60 s, 60 °C, 40×). Array 
analysis was performed once for every cell line. The threshold was manually set to 1 and CT values were uploaded 
as an easy-to-use Excel-based file. For further analysis software from the Qiagen Analysis Center was used. Data 
analysis is based on the ΔΔCT method with normalization of the raw data to housekeeping genes. A fold-change 
greater than one indicated up-regulation. The fold-regulation is equal to the fold-change. A fold-change less than 
one indicates down-regulation. The fold-regulation is the negative inverse of the fold-change. Calculation of 
fold-regulation correlates with fold-change values in a biologically meaningful way.
RT-qPCR validation of cell cycle genes. To confirm predominantly over-expressed GADD45A and 
CDKN1A and down-regulated SKP2 in the RT² Profiler™ PCR Array, gene expression was validated by RT-qPCR 
on a StepOnePlus™ System in 96-well fast plates with Power SYBR® Green Master Mix under standard condi-
tions (10 min, 95 °C; 15 sec, 95 °C and 60 sec, 60 °C, 40×). The threshold was manually set to 1. A “no template 
control” and a “no reverse transcriptase control” were run. A RT-qPCR reaction was set up in a total volume of 
20 μl containing 5 ng cDNA and 500 nM primers. Primers were predesigned and purchased from Integrated DNA 
Technologies (IDT, Leuven, Belgium). GAPDH: Hs.PT.39a.22214836, B2M: Hs.PT.58 v.18759587, GADD45A: 
Hs.PT.58.38974274, CDKN1A: Hs.PT.58.40874346.g, SKP2: Hs.PT.58.39891597.g.
Primer efficiencies were tested ranging between 90–100%. GAPDH or B2M levels were used as house-
keeping genes and for normalization. The relative expression of genes was calculated by the ∆∆CT method: 
ΔΔCT = (CT(target,untreated) −CT(ref,untreated)) − (CT(target,treated) −CT(ref,treated)); fold-change = 
2^(−∆∆CT)76.
Western Blot. For protein expression cells were incubated with viscum, TT and viscumTT in T175 flasks for 
3–24 h. The cells were washed twice and lysed using RIPA buffer (Carl Roth GmbH, Karlsruhe, Germany) or Lysis 
Buffer 17 (R&D systems, Minneapolis, MN) including proteinase inhibitor cocktail, PhoStop™ and pepstatin A. 
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Protein concentration was determined by Bradford reagent. Cell lysates (30 μg protein/lane) were separated on 
SDS-PAGE, transferred to nitrocellulose membranes (Trans-Blot™ Turbo Transfer System, Bio-Rad Laboratories 
GmbH, Munich, Germany) and blocked with 5% BSA in 50 mM Tris-buffered saline containing 0.05% Tween-20 
(TBST) for 1 h at room temperature. Blots were incubated overnight at 4 °C in TBST containing 5% BSA and pri-
mary antibody, washed twice in TBST and incubated 1 h with HRP-conjugated secondary antibodies (anti-rabbit, 
anti-mouse, Bio-Rad) then visualized by ECL (Thermo Scientific, Dreieich, Germany) on a Molecular Imager 
ChemiDoc (Bio-Rad). The following primary antibodies were used. GADD45A (#9662), CDKN1A (#2947), 
STAT3 (#4904), STAT3 Ser727 (#94994), STAT3 Tyr705 (#9145), pMAPK1/3 (ERK1/2, #4370), MYC (#9402) and 
BIRC5 (#2803) were purchased from Cell Signaling Technology (Danvers, MA, USA). SKP2 (sc-7164), pMAPK8 
(sc-6254), CCNA (sc-239), CCNE (sc-247), CDK2 (sc-163), CDK4 (sc-260), TP53 (sc-73566) and GAPDH 
(sc25778) were purchased from Santa Cruz Biotechnology (CA, USA). ß-actin (ACTB) directly conjugated to 
HRP (#A3854, Sigma-Aldrich) and CCND1 (ab134175, Abcam, Cambridge, GB) were also used.
siRNA, apoptosis detection and cell cycle analysis. For siRNA knock down experiments, U2OS and 
143B cells were reverse transfected with Lipofectamine™ RNAiMAX transfection reagent (Invitrogen, Karlsruhe, 
Germany) and penicillin/streptomycin-free, 0.04% FCS media for 48 h. After media exchange (RPMI or McCoys, 
penicillin/streptomycin-free, 10% FCS) cells were incubated with viscum, TT and viscumTT for a further 
24 h. Silencer TM Negative Control No.1 siRNA was used as non-targeting siRNA (AM4611, Thermo Scientific, 
Dreieich, Germany).







siRNA knock down was confirmed by western blotting. After transfection and treatment, cells were analyzed 
for either induction of apoptosis or cell cycle distribution. For apoptosis experiments, cells were washed twice 
with PBS, resuspended in 100 µL Annexin binding buffer and stained with Annexin V-APC (BD Biosciences, 
Franklin Lakes, NJ, USA) according to the manufacturer’s protocol. Finally, cells were stained with 1 µl PI 
(1 mg/mL) immediately before measuring and analyzed by flow cytometry (FACS Calibur, Becton Dickinson, 
Heidelberg, Germany). Data were evaluated using FlowJo® Software. For cell cycle distribution, siRNA trans-
fected cells were stained with 200 µL PI (50 µg/mL) as described above.
Inhibitor assay. For analyzing involvement of MAPK8 activation, U2OS and 143B cells were pre-treated 
with 5 μM SP600125 (Sigma-Aldrich) for 1 h. DMSO was used as solvent control. Additionally, pre-treated cells 
were further incubated with viscum, TT and viscumTT for 24 h. After treatment, cells were washed twice with 
PBS and analyzed for apoptotic cells with Annexin-V/PI as described above.
Osteosarcoma xenograft. Eight-week-old female NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac mice were obtained 
from Taconic Biosciences GmbH, Cologne, Germany. The mice were housed in a pathogen-free facility under 
pathogen-free conditions and fed autoclaved standard diet (Sniff, Soest, Germany) with acidified drinking water 
ad libitum. Saos-2 cells (1 × 107) were subcutaneously injected into the left flank and treatment started after day 
21, when tumor was palpable. Viscum (0.75/1.25/1.75 μg/kg ML I), TT (50/70/90 mg/kg OA) and the combi-
nation thereof viscumTT were administered intratumorally twice a week. Each concentration was given twice. 
Control mice were treated with CD. Mice were monitored daily for health and symptoms of toxicity, and tumor 
volume was measured twice weekly. On day 43 the mice were sacrificed by cervical dislocation or sacrificed earlier 
if considered moribund (tumor volume >1.2 cm3 or >10% body weight lost). The experiments were performed 
in accordance with German legislation on the care and use of laboratory animals and with the United Kingdom 
Coordinating Committee on Cancer Research Guidelines for the Welfare of Animals in Experimental Neoplasia 
so as to minimize suffering. Approval for the study was obtained from the Regional Office for Health and Social 
Affairs (LaGeSo, approval A0452/08).
Statistics. All in vitro experiments were independently performed thrice. RT² Profiler™ PCR Array analysis 
was performed once for each cell line and the fold-regulation cut-off was set to 2 and the p-value cut off was 
set to p ≤ 0.05. For each experiment, mean ± standard deviation (SD) were calculated. Two-way ANOVA and 
Tukey’s multiple comparison test were used for calculating significance. All significant results are indicated as 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001. For mice experiments, two-way ANOVA and Bonferroni’s 
multiple comparison test were used for determination of all significant differences between mouse xenograft 
groups. For synergistic induction of apoptosis (Figure S2A) the combination index (CI) was calculated by Bliss 
independent model: synergism (CI < 1), additive effect (CI = 1), antagonism (CI > 1)77. Effects and CI were cal-
culated as follows:
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= + − = + − ≤ ≤ ≤ ≤
=
+ −
Eab Ea Eb(1 Ea) Ea Eb EaEb where 0 Ea 1 and 0 Eb 1
CI Ea Eb EaEb
Eab
Ea-Effect of substance a (viscum), Eb-effect of substance b (TT), Eab-effect of the combination of substance 
a and b.
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